| |
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from
efavirenz in virologically-suppressed HIV-1-infected adolescents.
Jantarabenjakul W, Anugulruengkitt S, Kasipong N, et al
Antivir Ther. 2017 Oct 10.
Abstract
Rilpivirine Pharmacokinetics Without and With Darunavir/ritonavir once daily in
Adolescents and Young Adults.
Foca M, Yogev R, Wiznia A,
Pediatr Infect Dis J. 2016 May 16.
Abstract
Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With
Liver Cirrhosis Concomitantly Receiving Pantoprazole.
Calcagno A, Trentalange A, Simiele M, et al
Ther Drug Monit. 2015
Oct;37(5):695-6.
Abstract
Steady-state pharmacokinetics of rilpivirine under different meal
conditions in HIV-1-infected Ugandan adults.
Lamorde M, Walimbwa S, Byakika-Kibwika
P, et al
J Antimicrob Chemother. 2015 Feb 3. |
Abstract
Mechanism of action and pharmacokinetics of rilpivirine.
Portilla J, Estrada V.
Enferm Infecc Microbiol Clin. 2013
Jun;31S2:2-5.
Abstract
Effect of food on the pharmacokinetics of
emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen.
Ramanathan
S, Custodio J, Yin X,
Hepner M,
et al
J Int AIDS Soc.
2012 Nov 11;15(6):18333.
Abstract
FULL-TEXT ARTICLE
Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a
long-acting injectable antiretroviral formulation.
van 't Klooster G, Hoeben E, Borghys H,
Antimicrob Agents Chemother.
2010 May;54(5):2042-50.
Paper |
| |
UPLC-MS/MS method for the simultaneous quantification of three new
antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other
thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human
plasma.
Simiele
M, Ariaudo A, De Nicolň A,
et
aL
J Pharm Biomed Anal.
2017 Feb 3;138:223-230.
Abstract
S imultaneous
quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and
dolutegravir in mouse biological matrices by LC-MS/MS and its application to a
pharmacokinetic study.
Prathipati
PK, Mandal S, Destache CJ.
J
Pharm Biomed Anal. 2016 Jul
26;129:473-481
Abstract
Development And Validation Of A Chromatographic Uv Method For The Simultaneous
Quantification Of Dolutegravir And Rilpivirine In Human Plasma.
Cozzi V, Charbe N, Baldelli S, et al
Ther Drug Monit. 2016 Feb
16
Abstract
A liquid chromatography-tandem mass spectrometry assay for
quantification of rilpivirine and dolutegravir in human plasma.
Grégoire M, Deslandes G, Renaud C, et al
J Chromatogr B Analyt Technol Biomed Life Sci.
2014 Sep 16;971C:1-9
Abstract
A validated assay by liquid chromatography-tandem mass spectrometry
for the simultaneous quantification of elvitegravir and rilpivirine
in HIV positive patients.
Aouri M, Calmy A, Hirschel B, et al
J Mass Spectrom.
2013 May;48(5):616-625.
Abstract
|
A validated assay by liquid chromatography-tandem mass spectrometry for the
simultaneous quantification of elvitegravir and rilpivirine
in HIV positive patients.
Aouri M, Calmy A, Hirschel B, et al
J Mass Spectrom. 2013 May;48(5):616-625.
Abstract
Determination of rilpivirine (TMC-278) plasma concentrations by the conventional
LC-MS method.
Shibata M, Takahashi M, Kuwahara T,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18361
Abstract
Liquid chromatography-tandem mass spectrometric assay for the
non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma.
Burugula L, Pilli NR,
Makula A, et al
Biomed Chromatogr. 2012 Jun 22.
.
Abstract |
| |
|
In
Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine and MIV-150:
NNRTI Microbicides in Clinical Development for the Prevention of HIV-1
Infection.
Giacobbi
NS, Sluis-Cremer N.
Antimicrob
Agents Chemother. 2017 May 15.
Abstract
Rilpivirine and Doravirine have complementary efficacies against
NNRTI-Resistant HIV-1 mutants.
Smith SJ, Pauly GT, Akram A,
J Acquir Immune Defic Syndr. 2016 Apr 23
Abstract
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a
Mutation Conferring Rilpivirine Resistance.
Gray WT, Frey KM, Laskey SB,
ACS Med Chem Lett.
2015 Aug 31;6
Abstract
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral
naive adults.
Alvarez M, Monge S, Chueca N, et al
Clin Microbiol Infect . 2015
Jan;21(1):104.e1-5.
Abstract
Real-life rilpivirine resistance and potential emergence of an E138A-positive
HIV strain in north-eastern France.
Jeulin H, Foissac M, Boyer L, et al
J Antimicrob Chemother. 2014 Jul 8.
Abstract
Rilpivirine resistance and the dangerous liaisons with substitutions at
position 184 among patients infected with HIV-1: Analysis from a
national drug-resistance database (ARCA).
Rossotti R, Fonte L, Meini G,
et al
J Med Virol.
2014 May 17.
Abstract
Transmitted drug resistance to rilpivirine among antiretroviral-naďve
patients living with HIV from northern Poland.
Parczewski M, Urbańska A, Maciejewska K,
et
al
J Int AIDS Soc. 2014
Apr 17;17(1):18929.
Abstract
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical
samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Picchio GR, Rimsky LT, Van Eygen V,
Antivir Ther. 2014
Apr 4
Abstract
Rilpivirine, emtricitabine and tenofovir resistance
in HIV-1-infected rilpivirine-naive patients failing antiretroviral
therapy.
Lambert-Niclot
S, Charpentier C, Storto A, et al
J
Antimicrob Chemother. 2013 Dec 2
Abstract
The Connection Domain Mutation N348I in HIV-1 Reverse
Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts
the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication
Capacity.
Xu HT, Colby-Germinario SP, Oliveira M, et al
J Virol. 2013 Nov 13.
Abstract
Genetic barrier to the development of resistance
to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG
and B.
Fofana DB, Soulie C, Maiga AI, et al
J Antimicrob Chemother.
2013 Jul 5.
Abstract
Resistance profile of rilpivirine.
Imaz A, García F, di Yacovo
S, Llibre JM.
Enferm Infecc Microbiol Clin.
2013 Jun;31S2:36-43
Abstract
The Effect of Mutations at Position E138 in HIV-1 Reverse
Transcriptase and their Interactions with the M184I Mutation in Defining
Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine and Etravirine.
Xu HT, Colby-Germinario SP, Asahchop EL, et al
Antimicrob Agents Chemother.
2013 Apr 22.
Abstract
Prevalence of pre-existing resistance-associated mutations to
rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients
infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A, et al
J Antimicrob Chemother.
2013 Jan 29.
Abstract |
Distinct resistance patterns to etravirine and rilpivirine in
viruses containing nnrti mutations at baseline.
Asahchop EL, Wainberg MA, Oliveira M,
et al
AIDS.
2012 Dec 19.
Abstract
Preexisting mutations in the rilpivirine Phase III trials ECHO
and THRIVE: prevalence and impact on virologic response.
Vingerhoets J, Rimsky L, Van Eygen V,
et al
Antivir Ther.
2012 Sep 6.
Abstract
FULL-TEXT PDF ARTICLE
Biochemical Mechanism of HIV-1 Resistance to Rilpivirine.
Singh K, Marchand B, Rai DK, et al
J Biol Chem.
2012 Sep 6
Paper
Rilpivirine Resistance Mutations in HIV Patients Failing
Non-Nucleoside Reverse Transcriptase Inhibitor-Based Therapies.
Anta L, Llibre JM,
Poveda E, et al
AIDS.
2012 Aug 7.
Abstract |
Panel of
prototypical recombinant infectious molecular clones resistant to nevirapine,
efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL,
et al
Antimicrob Agents Chemother.
2012 Aug;56(8):4522-4
Paper
|
Minority variants associated with resistance to HIV-1
nonnucleoside reverse transcriptase inhibitors during
primary infection.
Nicot F, Saliou A,
Raymond S, et al
J
Clin Virol. 2012 Jul 19.
Abstract |
E138K and M184I mutations in HIV-1 reverse transcriptase co-emerge as a result
of APOBEC3 editing in the
absence of drug exposure.
Fourati S, Malet I,
Lambert S, et al
AIDS.
2012 Jun 12
Abstract
Panel of Prototypical Recombinant Infectious Molecular Clones
Resistant to Nevirapine, Efavirenz,
Etravirine, and Rilpivirine.
Balamane M, Varghese V, Melikian GL, et al
Antimicrob Agents Chemother.
2012 Jun 4.
Abstract |
Prevalence of TMC278 (rilpivirine) associated mutations
in the Frankfurt Resistance Database.
Reinheimer C, Doerr HW, Stürmer M. et al
J Clin Virol.
2011 Dec 30.
Abstract |
| |
|
| |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults
failing non-nucleoside
reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J,
Chetchotisakd P,
et al
Antivir Ther.
2011;16(7):1113-21
Abstract |
| |
FULL-TEXT ARTICLE
Long-term efficacy and safety of rilpivirine plus abacavir and
lamivudine in HIV-1 infected patients with undetectable viral
load.
Galizzi
N, Galli L, Poli A, Gianotti N, et a
lPLoS
One. 2018 Feb
16;13(2):e0191300
Paper
Efficacy
and safety of dolutegravir and rilpivirine dual therapy as a
simplification strategy: a cohort study.
Gantner P, Cuzin L, Allavena C, et al
HIV Med.
2017 Apr 26.
Abstract
Rilpivirine as a Treatment for HIV-infected Antiretroviral-naďve
Adolescents: Week 48 Safety, Efficacy, Virology and
Pharmacokinetics.
Lombaard
J, Bunupuradah T, Flynn PM,
et al
Pediatr
Infect Dis J.
2016 Nov;35(11):1215-1221.
Abstract
Rilpivirine, emtricitabine and tenofovir alafenamide:
single-tablet combination for the treatment of HIV-1 infection
in selected patients.
Ogbuagu O.
Expert Rev
Anti Infect Ther.
2016 Oct 31
Abstract
Rilpivirine as a Treatment for HIV-infected Antiretroviral-Naďve
Adolescents: Week 48 Safety, Efficacy, Virology and
Pharmacokinetics
Lombaard J, Bunupuradah T,
Flynn PM,
Pediatr Infect Dis J.
2016 Jun 10.
Abstract
FULL-TEXT
ARTICLE
Role of Rilpivirine and Etravirine in Efavirenz and
Nevirapine-Based Regimens Failure in a Resource-Limited Country:
A Cross- Sectional Study
Teeranaipong P,
Sirivichayakul S, Mekprasan S,
PLoS One.
2016 Apr 27;11(4):e0154221.
Paper
Rilpivirine vs. efavirenz-based single-tablet regimens in
treatment-naive adults: week 96 efficacy and safety from a
randomized phase 3b study.|
van Lunzen J, Antinori A, Cohen CJ,
et al
AIDS.
2016 Jan;30(2):251-9.
Abstract
Efficacy and safety of a switch to rilpivirine-based regimens in
treatment-experienced HIV-1-infected patients: a cohort study.
Gazaignes S, Resche-Rigon M, Gatey C, et al
Antivir Ther.
2015 Nov 13.
Abstract
Factors influencing the efficacy of rilpivirine in HIV-1 subtype
C in low- and middle-income countries.
Neogi U, Häggblom A, Singh K, et al
J Antimicrob Chemother.
2015 Oct 30.
Abstract
Patient-reported outcomes in the single-tablet regimen (STaR)
trial of rilpivirine/emtricitabine/tenofovir disoproxil
fumarate versus efavirenz/emtricitabine/tenofovir disoproxil
fumarate in antiretroviral treatment-naive adults infected with
HIV-1 through 48 weeks of treatment.
Wilkins EL, Cohen CJ, Trottier B, et al
AIDS Care. 2015 Oct 21:1-8
Abstract
Effectiveness and Safety of Rilpivirine, a Non-Nucleoside
Reverse Transcriptase Inhibitor, in Treatment-Naive Adults
Infected with HIV-1: A Meta-analysis.
Li SL, Xu P, Zhang L,
et al
HIV Clin Trials. 2014
Nov-Dec;15(6):261-8.
Abstract
Efficacy and safety of rilpivirine-based regimens in
treatment-experienced HIV-1 infected patients: a prospective
cohort study.
Gazaignes S, Resche-Rigon M, Yang C, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19796
Abstract
Lipid changes in HIV-patients switching to the
coformulated single tablet FTC/RPV/TDF (Eviplera®). Efficacy and
safety analysis. GeSida Study 8114.
Pérez-Hernández IA,
Palacios R, Mayorga M, et al
J Int AIDS Soc. 2014 Nov
2;17(4(Suppl 3)):19795.
Abstract
The Efficacy, Pharmacokinetics and Safety of a
Nevirapine to Rilpivirine Switch in Virologically Suppressed
HIV-1 Infected Patients.
Rokx C, Blonk M, Verbon A, et al
J Acquir Immune Defic
Syndr.
2014 Sep 22.
Abstract
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC)
regimen in 363 patients with virological vigilance assessment in
'real life'
Amiel C, Schneider V, Guessant S, et al
J Antimicrob Chemother.
2014 Aug 11.
Abstract
Rilpivirine Versus Efavirenz with
Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naďve
HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96
Pooled ECHO/THRIVE Subanalysis.
Behrens G, Rijnders B, Nelson M, et
al
AIDS Patient Care STDS. 2014
Mar 24.
Abstract
Outcomes In Older Versus Younger Patients Over 96
Weeks In Hiv-1-Infected Patients Treated With Rilpivirine Or
Efavirenz In Echo And Thrive
Ryan R, Dayaram
YK, Schaible D, et al
Curr HIV Res. 2014 Jan 28
Abstract
Data on rilpivirine in treatment-naďve patients. Lessons from
ECHO, THRIVE and STaR.
Domingo P, Ribera E.
Enferm Infecc Microbiol Clin.
2013 Jun;31S2:20-29.
Abstract
Rilpivirine Versus Efavirenz in HIV-1-Infected
Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week
Data from ECHO and THRIVE Studies.
Nelson
MR, Elion RA, Cohen CJm et al
HIV Clin Trials. 2013
May-Jun;14(3):81-91.
Abstract
96-week resistance analyses of rilpivirine in
treatment-naive, HIV-1-infected adults from the ECHO and THRIVE
Phase III trials.
Rimsky L, Van Eygen
V,
Hoogstoel A, et al
Antivir Ther.
2013 May
28
Abstract
Rilpivirine : a next-generation non-nucleoside analogue
for the treatment of HIV infection.
Fernández-Montero JV,
Vispo E, et al
Expert Opin Pharmacother.
2012 May;13(7):1007-14
Abstract
Combination therapies, effectiveness, and adherence in patients with
HIV infection: clinical utility of a single tablet
of emtricitabine, rilpivirine, and tenofovir.
Wainberg MA.HIV
AIDS (Auckl).
2013;5:41-9.
Abstract
Rilpivirine versus efavirenz in HIV-1 patients with baseline
viral load ≤100 000 copies/ml: week 48 Phase III analysis.
Molina JM, Clumeck N, Redant K, et al
AIDS. 2012 Dec 31.
Abstract |
A comparison of the ability of rilpivirine (TMC278) and selected
analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.
Johnson BC, Pauly GT,
Rai G, et al
Retrovirology. 2012 Dec 5;9(1):99.
Abstract
Week 96 efficacy and safety of rilpivirine in treatment-naďve,
HIV-1 patients in two Phase III randomised trials.
Cohen CJ, Molina JM, Cassetti I,
et al
AIDS. 2012 Dec 3.
Abstract
Rilpivirine. First-line treatment of
HIV infection: efavirenz is better documented.
[No authors listed]
Prescrire Int. 2012
Nov;21(132):262-5
Abstract |
|
Where rilpivirine meets with tenofovir, the start of a
new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol.
2012 Apr 5.
Abstract
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients
with hepatitis B virus/hepatitis C virus
coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE
trials.
Nelson M, Amaya G,
Clumeck N,
et al
J Antimicrob Chemother. 2012 Apr 24.
Abstract
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48
weeks in treatment-naďve,
HIV-1-infected patients: Pooled results from the phase 3 double-blind,
randomized ECHO and THRIVE trials.
Cohen C, Molina J, Cahn P, et al
J Acquir Immune Defic Syndr.
2012 Feb 16
Abstract |
| |
|
| |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in
treatment-naive adults infected with HIV-1 (ECHO):
a phase 3 randomised
double-blind active-controlled trial.
Molina JM, Cahn P, Grinsztejn
B. et al
Lancet.
2011 Jul
16;378(9787):238-46.
Abstract |
| |
|
| |
Rilpivirine versus efavirenz with two background nucleoside or nucleotide
reverse transcriptase inhibitors
in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised,
non-inferiority trial.
Cohen CJ, Andrade-Villanueva J, Clotet B,
et al
Lancet. 2011 Jul 16;378(9787):229-37.
Abstract
|
| |
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
| |
A randomized, controlled trial of the effect of rilpivirine versus efavirenz on
cardiovascular risk in healthy volunteers.
Gupta SK, Slaven JE, Kamendulis LM, Liu Z.
J Antimicrob Chemother. 2015 Jul
131
Abstract
Analysis of Lipid Levels and Changes in Body Fat Distribution in
Treatment-Naive, HIV-1-Infected Adults Treated with Rilpivirine or Efavirenz
Over 96 Weeks in the ECHO and THRIVE Trials.
Tebas P, Sension M, Arribas J, et al
Clin Infect Dis. 2014 Apr
11.
Abstract
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks
among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz
in a Phase III trial (ECHO).
Wohl DA, Orkin C, Doroana M, et al
Antivir Ther.
2014 Jan 16.
Abstract
Liver Toxicity in HIV-Infected Patients Receiving
Novel Second-Generation Nonnucleoside Reverse Transcriptase
Inhibitors Etravirine and Rilpivirine.
Casado JL.
AIDS Rev.
2013 Jul-Sep;15(3):139-45.
Abstract |
| |
MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and
abacavir; effect on intestinal absorption.
Reznicek J, Ceckova M, Ptackova Z,
et al
Antimicrob Agents Chemother.
2017 Jul 10.
Abstract
Evaluation of Drug-Drug Interactions between Direct-Acting
Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral
Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and
Rilpivirine.
Khatri A, Dutta S, Dunbar M,
et al
Antimicrob Agents Chemother.
2016 Apr 22;60(5):2965-71.
Abstract |
Pharmacokinetic interaction between etravirine or
rilpivirine and telaprevir in healthy volunteers: A randomized,
two-way crossover trial.
Kakuda TN, Leopold L, Nijs S, et al
J Clin Pharmacol.
2014 May;54(5):563-73.
Abstract
The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative
volunteers.
Crauwels HM, van Heeswijk RP, Vandevoorde A,
J Clin Pharmacol. 2013 Nov 6.
Abstract
Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and
norethindrone in healthy volunteers.
Crauwels HM, van Heeswijk RP, Buelens A, et al
Int J Clin Pharmacol Ther.
2013 Oct 28.
Abstract
Lack of Pharmacokinetic Interaction Between Rilpivirine and Integrase Inhibitors
Dolutegravir and GSK1265744.
Ford SL, Gould E, Chen S, et al
Antimicrob Agents Chemother.
2013 Aug 26.
Abstract
Pharmacokinetic interactions
Arazo Garcés P, Los Santos Gil ID.
Enferm Infecc Microbiol Clin.
2013 Jun;31S2:12-19
Abstract
Clinical Perspective on Drug‑Drug Interactions with the Non-nucleoside Reverse
Transcriptase Inhibitor Rilpivirine.
Crauwels H, van Heeswijk RP, Stevens M, et al
AIDS Rev. 2013 May 17;15(2):87-101.
Abstract |
| |
Switch from unboosted protease inhibitor to a single-tablet regimen
containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A, Riccardi N, Taramasso L, et al
Int
J Antimicrob Agents. 2016
Nov;48(5):551-554.
Abstract
Efficacy and safety of dolutegravir and rilpivirine dual therapy
as a simplification strategy: a cohort study.
Gantner P, Cuzin L, Allavena C, et al
HIV Med.
2017 Apr 26.
Abstract
Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of
a Triple-Therapy Regimen in a Critically Ill Patient with HIV.
Turley SL, Fulco PP.
J Int Assoc Provid AIDS Care. 2017
Abstract
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1
Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir
Disoproxil Fumarate in the SPIRIT Study.
Porter DP, Toma J, Tan Y,
HIV Clin Trials.
2016 Feb;17(1):29-37.
Abstract
Improvement of lipid profiles when switching from efavirenz
to rilpivirine in HIV-infected patients with dyslipidemia.
Thamrongwonglert P, Chetchotisakd P,
Anunnatsiri S, Mootsikapun P.
HIV Clin Trials. 2016 Jan 7:1-5.
Abstract
Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in
effective salvage antiretroviral therapy.
Leporrier J, Etienne M, Chapuzet C, et al
J Clin Virol. 2014 Aug;60(4):428-30
Abstract
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected
patients with an isolated K103N mutation acquired during prior nonnucleoside
reverse transcriptase inhibitor therapy.
Rokx C, Verbon A, Rijnders B.
HIV Med. 2014 Apr
16.
Abstract
Efficacy and safety 48 weeks after
switching from efavirenz to
rilpivirine using
emtricitabine/tenofovir disoproxil
fumarate-based single-tablet regimens.
Mills AM, Cohen C, Dejesus E ,et al
HIV Clin Trials. 2013
Sep-Oct;14(5):216-33.
Abstract
Potential role of rilpivirine in simplification regimens.
Casado JL, Moreno S.
Enferm Infecc Microbiol Clin. 2013
Jun;31S2:30-35.
Abstract |
|
|
Rilpivirine Main Page
